Chronotherapy for reduction of cardiovascular risk

被引:5
|
作者
Hermida, Ramon C. [1 ,2 ]
Hermida-Ayala, Ramon G. [3 ]
Smolensky, Michael [2 ]
机构
[1] Univ Vigo, Atlantic Res Ctr Informat & Commun Technol AtlanT, Lab Bioingn & Cronobiol, Vigo, Spain
[2] Univ Texas Austin, Dept Biomed Engn, Cockrell Sch Engn, Austin, TX 78712 USA
[3] Circadian Ambulatory Technol & Diagnost CAT&D, Santiago de Compostela, La Coruna, Spain
来源
MEDICINA CLINICA | 2020年 / 154卷 / 12期
关键词
Chronobiology; Chronotherapy; Ambulatory blood pressure monitoring; Asleep blood pressure; Sleep-time relative blood pressure decline; Cardiovascular risk; Diagnosis of hypertension; Diabetes; Kidney disease; AMBULATORY BLOOD-PRESSURE; URINARY ALBUMIN EXCRETION; KIDNEY-DISEASE PATIENTS; HYPERTENSIVE PATIENTS; ANTIHYPERTENSIVE THERAPY; ACTIVE TREATMENT; DOUBLE-BLIND; SLEEP-TIME; BEDTIME; PLACEBO;
D O I
10.1016/j.medcli.2020.02.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Numerous prospective studies establish that elevated asleep blood pressure (BP) constitutes a significant cardiovascular disease (CVD) risk factor, irrespective of daytime office BP measurements or awake and 24 h BP measurements. Moreover, except for a small number of studies with flawed methodology, multiple clinical trials of high consistency document significantly better BP-lowering efficacy of hypertension medication and their combinations when ingested at bedtime compared to upon awakening as is customary. Additionally, recent trials conclude bedtime hypertension chronotherapy markedly reduces CVD risk not only in the general population, but also in more vulnerable patients of advanced age, with kidney disease, diabetes, or resistant hypertension. Collectively, these results call for a new definition of true arterial hypertension and its proper diagnosis and management. (C) 2020 Elsevier Espafia, S.L.U. All rights reserved.
引用
收藏
页码:505 / 511
页数:7
相关论文
共 50 条
  • [1] Bedtime hypertension chronotherapy best reduces cardiovascular disease risk as documented by MAPEC and Hygia Chronotherapy outcomes trials
    Hermida, Ramon C.
    Mojon, Artemio
    Fernandez, Jose R.
    [J]. CHRONOBIOLOGY INTERNATIONAL, 2020, 37 (05) : 731 - 738
  • [2] Cardiovascular Risk Reduction
    Strauer, B. E.
    Haller, H.
    [J]. INTERNIST, 2012, 53 (01): : 5 - 5
  • [3] Cardiovascular Risk Reduction
    Gidding, Samuel
    Kavey, Rae-Ellen W.
    [J]. PEDIATRIC ANNALS, 2012, 41 (07): : 280 - 281
  • [4] Chronotherapy of cardiovascular pathologies: a hopeful strategy
    Simko, Fedor
    Baka, Tomas
    [J]. THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2022, 13
  • [5] BIORHYTHMS AND CHRONOTHERAPY IN CARDIOVASCULAR-DISEASE
    COOKE, HM
    LYNCH, A
    [J]. AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1994, 51 (20): : 2569 - 2580
  • [6] Ramipril and cardiovascular risk reduction
    Nichols, WW
    Schuler, B
    O'Rourke, MF
    [J]. CIRCULATION, 2002, 105 (25) : A194 - A194
  • [7] Cardiovascular risk reduction in the pharmacy
    Bouwer, Annatjie
    [J]. SA PHARMACEUTICAL JOURNAL, 2011, 78 (08) : 27 - 30
  • [8] Hypertriglyceridemia and cardiovascular risk reduction
    Jacobson, Terry A.
    Miller, Michael
    Schaefer, Ernst J.
    [J]. CLINICAL THERAPEUTICS, 2007, 29 (05) : 763 - 777
  • [9] Niacin for Reduction of Cardiovascular Risk
    Rembold, Christopher M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (20): : 1940 - 1941
  • [10] Salt reduction and cardiovascular risk
    Michael H Alderman
    [J]. Journal of Human Hypertension, 1999, 13 : 645 - 645